Literature DB >> 2553809

Natural killer cell and granulocyte Fc gamma receptor III (CD16) differ in membrane anchor and signal transduction.

P Selvaraj1, O Carpén, M L Hibbs, T A Springer.   

Abstract

CD16 is a low affinity Fc gamma R III expressed on granulocytes, macrophages and large granular lymphocytes, the mediators of antibody-dependent cellular cytotoxicity and NK. The occupancy of CD16 by aggregated IgG on large granular lymphocytes induces expression of activation markers, release of inflammatory mediators and triggering of effector functions such as antibody-dependent cellular cytotoxicity. Recently we and others described that CD16 is anchored to the membrane of granulocytes via a phosphatidylinositol glycan moiety. Here we show that the CD16 molecule expressed on NK cells, cultured monocytes, and lung macrophages is not phosphatidylinositol glycan moiety anchored. It is not released with phosphatidylinositol-specific phospholipase C, and after removal of N-linked carbohydrate is 5 to 7 kDa larger than the granulocyte CD16 molecule, strongly suggesting the presence of transmembrane and cytoplasmic protein domains. Redirected killing of hybridoma targets expressing anti-CD16 surface Ig shows that NK cell CD16 is unable to do so. These findings demonstrate that NK cell and granulocyte CD16 have different membrane anchors and indicate that the type of membrane anchor is an important biologic mechanism for regulating the functional capacity of surface receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553809

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Analysis of competition binding between soluble and membrane-bound ligands for cell surface receptors.

Authors:  P Li; P Selvaraj; C Zhu
Journal:  Biophys J       Date:  1999-12       Impact factor: 4.033

2.  Concurrent and independent binding of Fcgamma receptors IIa and IIIb to surface-bound IgG.

Authors:  T E Williams; S Nagarajan; P Selvaraj; C Zhu
Journal:  Biophys J       Date:  2000-10       Impact factor: 4.033

3.  Concurrent binding to multiple ligands: kinetic rates of CD16b for membrane-bound IgG1 and IgG2.

Authors:  T E Williams; P Selvaraj; C Zhu
Journal:  Biophys J       Date:  2000-10       Impact factor: 4.033

4.  The specificity of the IgA receptor purified from human neutrophils.

Authors:  R L Mazengera; M A Kerr
Journal:  Biochem J       Date:  1990-11-15       Impact factor: 3.857

5.  CD27/CD70 interaction directly induces natural killer cell killing activity.

Authors:  F C Yang; K Agematsu; T Nakazawa; T Mori; S Ito; T Kobata; C Morimoto; A Komiyama
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

Review 6.  The Role and Function of Fcγ Receptors on Myeloid Cells.

Authors:  Stylianos Bournazos; Taia T Wang; Jeffrey V Ravetch
Journal:  Microbiol Spectr       Date:  2016-12

7.  Measuring diffusion and binding kinetics by contact area FRAP.

Authors:  Timothy P Tolentino; Jianhua Wu; Veronika I Zarnitsyna; Ying Fang; Michael L Dustin; Cheng Zhu
Journal:  Biophys J       Date:  2008-04-04       Impact factor: 4.033

8.  Altered expression of Fc gammaRIII (CD16) on polymorphonuclear neutrophils from individuals with human immunodeficiency virus type 1 disease and pulmonary tuberculosis.

Authors:  S Meddows-Taylor; D J Martin; C T Tiemessen
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

Review 9.  Signaling by Antibodies: Recent Progress.

Authors:  Stylianos Bournazos; Taia T Wang; Rony Dahan; Jad Maamary; Jeffrey V Ravetch
Journal:  Annu Rev Immunol       Date:  2017-04-26       Impact factor: 28.527

10.  Glycosyl-phosphatidylinositol-anchored and transmembrane forms of CD46 display similar measles virus receptor properties: virus binding, fusion, and replication; down-regulation by hemagglutinin; and virus uptake and endocytosis for antigen presentation by major histocompatibility complex class II molecules.

Authors:  G Varior-Krishnan; M C Trescol-Biémont; D Naniche; C Rabourdin-Combe; D Gerlier
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.